Research programme: cardiovascular disease therapeutic - Daewoong PharmaceuticalAlternative Names: IMD5; Incrementally modified drug 5
Latest Information Update: 16 Jul 2016
At a glance
- Originator Daewoong Pharmaceutical
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Atherosclerosis in South Korea
- 16 Jul 2016 No recent reports of development identified for research development in Hyperlipidaemia in South Korea
- 25 Feb 2011 Early research in Hyperlipidaemia in South Korea (unspecified route)